Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
Karyopharm Therapeutics Inc
Sebastian Grosicki; Maryana Simonova; Ivan Spicka; Ludek Pour; Iryrna Kriachok; Maria Gavriatopoulou; Halyna Pylypenko; Holger W Auner; Xavier Leleu; Vadim Doronin; Ganna Usenko; Nizar J Bahlis; Roman Hajek; Reuben Benjamin; Tuphan K Dolai; Dinesh K Sinha; Christopher P Venner; Mamta Garg; Mercedes Gironella; Artur Jurczyszyn; Pawel Robak; Monica Galli; Craig Wallington-Beddoe; Atanas Radinoff; Galina Salogub; Don A Stevens; Supratik Basu; Anna M Liberati; Hang Quach; Vesselina S Goranova-Marinova; Jelena Bila; Eirini Katodritou; Hanna Oliynyk; Sybiryna Korenkova; Jeevan Kumar; Sundar Jagannath; Phillipe Moreau; Moshe Levy; Darrell White; Moshe E Gatt; Thierry Facon; Maria V Mateos; Michele Cavo; Donna Reece; Larry D Anderson; Jean-Richard Saint-Martin; Jacqueline Jeha; Anita A Joshi; Yi Chai; Lingling Li; Vishnuvardhan Peddagali; Melina Arazy; Jatin Shah; Sharon Shacham; Michael G Kauffman; Meletios A Dimopoulos; Paul G Richardson; Sosana Delimpasi